Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
Home Page: www.aeriepharma.com
AERI Technical Analysis
4301 Emperor Boulevard
Durham,
NC
27703
United States
Phone:
919 237 5300
Officers
| Name | Title |
|---|---|
| Mr. Raj Kannan | CEO, Principal Financial Officer & Director |
| Dr. Casey C. Kopczynski Ph.D. | Co-Founder, Chief Innovation Officer & Head of Research and External Innovation |
| Mr. John W. LaRocca Esq. | Gen. Counsel & Sec. |
| Mr. Peter F. Lang | Chief Financial Officer |
| Dr. Michelle Senchyna Ph.D. | Head of Clinical Devel. & Operations |
| Mr. Jeffrey M. Calabrese CPA | VP of Fin. & Principal Accounting Officer |
| Ms. Carolyn McAuliffe | Sr. Director of Communications |
| Ms. Wanda Francies | Head of HR |
| Mr. Marvin J. Garrett | Head of Regulatory Affairs & Quality Assurance |
| Mr. Craig R. Skenes | Head of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 34.2559 |
| Price-to-Sales TTM: | 3.5225 |
| IPO Date: | 2013-10-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 376 |